Rapport Therapeutics to Present Insights on RAP-219
Rapport Therapeutics, Inc. (NASDAQ: RAPP), a pioneering biotechnology entity, is gearing up to unveil impressive findings from its Phase 2a clinical trial focused on RAP-219, a promising treatment for focal onset seizures (FOS). The presentation will occur during the 2025 American Epilepsy Society Annual Meeting, scheduled between December 5–9.
Highlighting Key Findings
At the annual meeting, Rapport will share crucial data derived from its Phase 2a study. This new analysis will delve into additional efficacy measures, examining how RAP-219 behaves not just during the initial treatment phase, but across the entire treatment timeline. The findings regarding how baseline disease severity influences treatment response and RAP-219's impact on seizure severity are particularly noteworthy.
Poster Session Presentation Details
During the poster sessions, Rapport will highlight the following:
- Abstract Title: Efficacy and Tolerability of RAP-219, a Potential First-in-Class Negative Allosteric Modulator of ?8 Transmembrane AMPA Receptor Associated Protein: Impact on RNS Long Episodes and Focal Seizures
Poster: 2.489
Date: Sunday, December 7
Time: 10:00 a.m. – 4:00 p.m. ET - Abstract Title: RAP-219: A Differentiated ASM Targeting Restricted Brain Expression of Transmembrane AMPA Receptor Protein ?8
Poster: 3.355
Date: Monday, December 8
Time: 8:00 a.m. – 2:00 p.m. ET
Exhibit Room Details
A dedicated Scientific Exhibit Room will be part of the event's program. This space will showcase all the aforementioned posters and additional notable findings from the trial, ensuring attendees have direct access to vital information:
Date: Sunday, December 7
Time: 8:00 – 11:00 a.m. ET
Location: GWCC B303, Level 3
Additional Posters
The following essential topics will also be included in the presentations:
- Effect of RAP-219 on Long Episodes and Clinical Seizures in Adults with Drug-Resistant Focal Seizures and an Implanted Responsive Neurostimulator (RNS) System by Baseline Long Episode and Clinical Seizure Frequencies: A Post Hoc Analysis of a Phase 2a Proof-of-Concept Study
- Effect of RAP-219 on Seizure Severity in Adults with Drug-Resistant Focal Seizures and an Implanted Responsive Neurostimulator (RNS) System
- Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Volunteers
- Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219
- Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency
- Evolution of RAP-219 for the Treatment of Epilepsy
About RAP-219
RAP-219 represents a transformative approach in epilepsy treatment, as a first-in-class negative allosteric modulator that specifically targets the ?8 subunit of AMPA receptors. This precision medicine aims to effectively address focal seizures by concentrating its action in brain areas directly involved in seizure generation. By contrasting itself with traditional therapies, which can affect broader neural pathways and cause side effects, RAP-219 holds the promise of a more tolerable treatment option for patients.
About Rapport Therapeutics
Rapport Therapeutics stands at the forefront of neurological and psychiatric research, focusing on personalized medicine through its innovative technology platform. The ability to target specific neurological pathways through small molecules distinguishes its pipeline, spotlighting the potential of RAP-219 for conditions like bipolar disorder and peripheral neuropathic pain. With ongoing advancements and trials, Rapport is committed to redefining treatment landscapes in neuroscience.
Stay Updated on the Latest Developments
The company actively shares updates and detailed metrics regarding RAP-219 and its broader pipeline through its Investor Relations website and social media platforms. Stakeholders are encouraged to review these channels for forthcoming information on new discoveries, regulatory advancements, and trials.
Frequently Asked Questions
What is RAP-219?
RAP-219 is a clinical-stage medication aimed at treating focal onset seizures by acting on specific brain receptors to enhance efficacy and tolerability.
When will the results of the RAP-219 Phase 2a study be presented?
The findings will be shared at the American Epilepsy Society Annual Meeting in December 2025.
How does RAP-219 differ from traditional epilepsy medications?
Unlike traditional treatments, RAP-219 selectively targets receptors associated with focal seizures, aiming to reduce side effects.
What other conditions could RAP-219 potentially treat?
In addition to epilepsy, RAP-219 is being explored as a treatment option for bipolar disorder and peripheral neuropathic pain.
Where can I follow Rapport Therapeutics for updates?
Investors and interested parties can follow Rapport on its Investor Relations website and LinkedIn for the latest news and updates.
